Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)

Next Previous
Trial Profile

Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Churg-Strauss syndrome; Granulomatosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top